Amylin vs Eloralintide
Co-secreted with insulin; the satiety and gastric-emptying partner. A selective, long-acting amylin agonist that reaches GLP-1-class weight loss without touching the GLP-1 receptor. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Amylin IAPP | Eloralintide | |
|---|---|---|
| Also known as | — | — |
| Type | Endogenous | Analog |
| Evidence | Established | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Islet amyloid polypeptide (37 aa) | Selective long-acting amylin analog (acylated 37 aa peptide) |
| Receptor / target | Amylin receptors (calcitonin receptor + RAMP complexes) | Amylin receptors (calcitonin receptor + RAMP), AMY1-selective |
| Molecular weight | ~3,903.3 Da | ~4,526 Da |
| Half-life | ||
| Based on | Native hormone | Amylin |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Amylin and Eloralintide?
- Amylin is an endogenous hormone; Eloralintide is an engineered analog based on Amylin. Amylin signals at Amylin receptors (calcitonin receptor + RAMP complexes); Eloralintide signals at Amylin receptors (calcitonin receptor + RAMP), AMY1-selective.
- How do the half-lives of IAPP and Eloralintide compare?
- The reported circulating half-life of Amylin is ~13 min (native); Eloralintide is ~13–15 days (310–366 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Eloralintide vs Amylin. Or open the interactive comparison tool to add more molecules.